Community/Retail

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

The Opioid and Naloxone program at North Dakota State University School of Pharmacy aims to make a difference.

Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.

Arthriten may offer relief from minor arthritis pain.

The survey results come as the ACIP evaluates data to provide guidance for flu vaccines in older adults.

Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.

Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.

By maintaining relationships, pharmacists can create a successful practice and pharmaceutical care services will expand.

Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.

Tocilizumab (Actemra) is indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.

Tecnu Rash Relief Spray treats skin irritation caused by sunburn, minor skin irritations, insect bites, and other minor skin issues.

Appropriate screening tools can help identify individuals at increased risk for or with anxiety, depression, and eating disorders.

Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.

Congress expected the FDA to draft a memorandum of understanding on interstate distributions of compounded medications that states would be willing to sign, but that’s not what the agency did.

The coexistence of hepatitis B virus (HBV) surface antigens and antibodies against are an atypical serological profile for patients with chronic HBV infections.

Teriparatide injection (Forteo) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

D-Mannose can aid in maintaining urinary and bladder health.

Areas for improvement include the business model, health care team buy-in, patient engagement, and technology.

It is the role of the pharmacist to ensure patients are adequately counseled on the adverse effects and potential harms of codeine.

The topical therapy demonstrated significant improvements in the study, based on IGA success and other endpoints, according to investigators.

PrEP therapy has revolutionized HIV treatment by protecting patients who are high risk for acquiring the virus.

Risankizumab-rzaa (Skyrizi) is the first and only specific interleukin-23 inhibitor approved for the treatment of adults with moderately to severely active Crohn disease.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Uqora Target flushes the urinary tract to help avoid urinary tract infections.

The role of the pharmacist in sickle cell disease management revolves around appropriate pain management.

The study has met its primary endpoint, with approximately 78.4% of women who continued taking the drug achieving the sustained responder rate through week 76.